{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:38Z","timestamp":1788869318717,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:50:15Z","timestamp":1782575415000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6980-3926","authenticated-orcid":false,"given":"Joseph Tod","family":"Guidry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Catherine","family":"Pietanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cllc.2026.06.007_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd.2017.65","article-title":"Trial watch: trends in clinical trial design complexity","volume":"16","author":"Getz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cllc.2026.06.007_bib0002","unstructured":"Tufts University School of Medicine. Protocol complexity continues to increase, challenging clinical trial performance. Tufts Center for the Study of Drug Development Impact Report. Boston, MA; 2021. 23. https:\/\/csdd.tufts.edu\/publications\/impact-reports."},{"key":"10.1016\/j.cllc.2026.06.007_bib0003","unstructured":"US Food and Drug Administration. Conducting clinical trials with decentralized elements, guidance for industry, investigators and other interested parties, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements. Accessed: November 17, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0004","unstructured":"US Food and Drug Administration. Integrating randomized controlled trials for drug and biological products into routine clinical practice, guidance for industry; draft guidance, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/integrating-randomized-controlled-trials-drug-and-biological-products-routine-clinical-practice. Accessed: November 17, 2025."},{"issue":"6","key":"10.1016\/j.cllc.2026.06.007_bib0005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/2159-8290.CD-NB2023-0031","article-title":"Pragmatica-lung trial to mimic \u201creal-world\u201d conditions","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.cllc.2026.06.007_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14740\/wjon1575","article-title":"Neurological adverse effects of immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"14","author":"Khalid","year":"2023","journal-title":"World J Oncol"},{"issue":"35","key":"10.1016\/j.cllc.2026.06.007_bib0007","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.17634","article-title":"Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"224","key":"10.1016\/j.cllc.2026.06.007_bib0008","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davilia","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.cllc.2026.06.007_bib0009","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cllc.2026.06.007_bib0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.cllc.2026.06.007_bib0011","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.cllc.2026.06.007_bib0012","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against VEGF: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cllc.2026.06.007_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.cllc.2026.06.007_bib0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.06.007_bib0015","unstructured":"US Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations, guidance for industry, investigators, and other stakeholders, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations. Accessed: November 17, 2025."},{"issue":"9","key":"10.1016\/j.cllc.2026.06.007_bib0016","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: aSCO-Friends of Cancer Research join research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cllc.2026.06.007_bib0017","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jtho.2018.02.013","article-title":"Making lung cancer clinical trials more inclusive: recommendations for expanding eligibility criteria","volume":"13","author":"Bonomi","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.06.007_bib0018","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2022.1664","article-title":"A new approach to simplifying and harmonizing cancer clinical trials \u2013 standardizing eligibility criteria","volume":"8","author":"Gerber","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.06.007_bib0019","unstructured":"US Food and Drug Administration. Cancer clinical trial eligibility criteria: performance status; draft guidance, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-performance-status. Accessed: November 17, 2025."},{"issue":"Suppl 2","key":"10.1016\/j.cllc.2026.06.007_bib0020","first-page":"47","article-title":"Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy","volume":"9","author":"Hamo","year":"2015","journal-title":"Clin Med Insights Cardiol"},{"issue":"6","key":"10.1016\/j.cllc.2026.06.007_bib0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2026.06.007_bib0022","unstructured":"US Food and Drug Administration. Cancer clinical trial eligibility criteria: patients with HIV, Hepatitis B Virus, or Hepatitis C Virus infections, guidance for industry, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus. Accessed: November 17, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0023","unstructured":"US Food and Drug Administration. Considerations for including tissue biopsies in clinical trials, guidance for industry, investigators, institutions, and institutional review boards; draft guidance, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-including-tissue-biopsies-clinical-trials. Accessed: November 17, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0024","unstructured":"US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims, guidance for industry, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed: November 17, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0025","unstructured":"US Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials, guidance for industry, Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials. Accessed: November 17, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0026","unstructured":"European Medicines Agency (EMA). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products_en.pdf. Accessed: December 30, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0027","unstructured":"European Medicines Agency (EMA). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed: December 30, 2025."},{"key":"10.1016\/j.cllc.2026.06.007_bib0028","unstructured":"European Medicines Agency (EMA). Reflection paper on patient experience data. Available at: https:\/\/www.ema.europa.eu\/en\/patient-experience-data-ped-reflection-paper. Accessed: January 1, 2025."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:04Z","timestamp":1788866344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000872"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}